Expression of different isoforms of utrophin in human muscle; potentials for therapy of Duchenne muscular dystrophy

Expression of different isoforms of utrophin in human muscle; potentials for therapy of Duchenne muscular dystrophy

Detalhes bibliográficos
Main Authors:	Sewry, C, Nowak, K, Ehmsen, J, Davies, K
Formato:	Conference item
Publicado em:	2004

Registos relacionados

Utrophin in the therapy of Duchenne Muscular Dystrophy
Por: Potter, A, et al.
Publicado em: (2006)

The role of utrophin in the potential therapy of Duchenne muscular dystrophy.
Por: Perkins, K, et al.
Publicado em: (2002)

Utrophin upregulation in Duchenne muscular dystrophy.
Por: Hirst, R, et al.
Publicado em: (2005)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
Por: Guiraud, S, et al.
Publicado em: (2019)

A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours.
Por: Sewry, C, et al.
Publicado em: (2005)

Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in Duchenne and Becker muscular dystrophy muscle biopsies
Por: Janghra, N, et al.
Publicado em: (2016)

Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy.
Por: Griffin, J, et al.
Publicado em: (2002)

Identification of new chemical compounds with upregulate utrophin for the therapy of Duchenne muscular dystrophy
Por: Fairclough, R, et al.
Publicado em: (2012)

Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
Por: Narinder Janghra, et al.
Publicado em: (2016-01-01)

Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy
Por: Fairclough, R, et al.
Publicado em: (2008)

New orally available compounds which modulate utrophin expression for the therapy of Duchenne muscular dystrophy (DMD)
Por: Fairclough, R, et al.
Publicado em: (2014)

Utrophin in therapy of Duchenne muscular distrophy
Por: Fisher, R
Publicado em: (2001)

Analysis of the transcriptional control of utrophin promoters as a therapeutic strategy for Duchenne muscular dystrophy (DMD).
Por: Perkins, K, et al.
Publicado em: (2000)

Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.
Por: Chancellor, DR, et al.
Publicado em: (2011)

Utrophin upregulation and microRNAs - two avenues of Duchenne muscular dystrophy therapy research
Por: Bareja, A
Publicado em: (2011)

Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy
Por: Perkins, K, et al.
Publicado em: (2018)

Mechanism of action studies of the utrophin modulator ezutromid for the treatment of Duchenne muscular dystrophy
Por: Wilkinson, I
Publicado em: (2019)

Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy
Por: Ruo Wu, et al.
Publicado em: (2022-11-01)

Progress in therapy for Duchenne muscular dystrophy.
Por: Fairclough, R, et al.
Publicado em: (2011)

Progress in therapy for Duchenne muscular dystrophy
Por: Fairclough, R, et al.
Publicado em: (2011)

The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy.
Por: Perkins, K, et al.
Publicado em: (2001)

Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
Por: Nowak, K, et al.
Publicado em: (2004)

Muscle X-inactivation patterns and dystrophin expression in Duchenne muscular dystrophy carriers.
Por: Matthews, P, et al.
Publicado em: (1995)

Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)
Por: Tinsley, J, et al.
Publicado em: (2013)

Metabolic dysfunction and altered mitochondrial dynamics in the utrophin-dystrophin deficient mouse model of duchenne muscular dystrophy.
Por: Meghna Pant, et al.
Publicado em: (2015-01-01)

Regenerative biomarkers for Duchenne muscular dystrophy
Por: Guiraud, S, et al.
Publicado em: (2019)

Duchenne muscular dystrophy - past, present and future
Por: Davies, K
Publicado em: (2002)

From diagnosis to therapy in Duchenne muscular dystrophy
Por: Babbs, A, et al.
Publicado em: (2020)

Pharmacological advances for treatment in Duchenne muscular dystrophy
Por: Guiraud, S, et al.
Publicado em: (2017)

Cardiac therapies for Duchenne muscular dystrophy
Por: Md Nur Ahad Shah, et al.
Publicado em: (2023-07-01)

Rehabilitation therapy of Duchenne muscular dystrophy
Por: Cheng ZHANG, et al.
Publicado em: (2012-06-01)

Understanding the endothelial function of utrophin.
Por: Ehmsen, J, et al.
Publicado em: (2002)

Duchenne Muscular Dystrophy
Por: J Gordon Millichap
Publicado em: (1989-05-01)

Regenerative biomarkers for Duchenne muscular dystrophy
Por: Simon Guiraud, et al.
Publicado em: (2019-01-01)

Therapeutic approaches for Duchenne muscular dystrophy
Por: Roberts, TC, et al.
Publicado em: (2023)

Medical management of muscle weakness in Duchenne muscular dystrophy.
Por: Sarah R Rivera, et al.
Publicado em: (2020-01-01)

Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.
Por: Fairclough, R, et al.
Publicado em: (2013)

Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy
Por: Mary Chesshyre, et al.
Publicado em: (2022-04-01)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.
Por: Goyenvalle, A, et al.
Publicado em: (2011)

Nitric Oxide and l-Arginine Cause an Accumulation of Utrophin at the Sarcolemma: A Possible Compensation for Dystrophin Loss in Duchenne Muscular Dystrophy
Por: Emmanuel Chaubourt, et al.
Publicado em: (1999-12-01)